HuGE Literature Finder
Records
1
-
5
The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients. PloS one 2021 16 (4): e0250597. Furuse Maizumi, Hosomi Shuhei, Nishida Yu, Itani Shigehiro, Nadatani Yuji, Fukunaga Shusei, Otani Koji, Tanaka Fumio, Nagami Yasuaki, Taira Koichi, Kamata Noriko, Watanabe Toshio, Watanabe Kenji, Fujiwara Yasuhi |
CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients. International journal of molecular sciences 2020 6 21 (12): . Yamamoto Yuki, Nakase Hiroshi, Matsuura Minoru, Maruyama Shihoko, Masuda Satohi |
Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFa biologic for ulcerative colitis: a case report. BMC cancer 2016 16 304. Henderson Sara L, Teft Wendy A, Kim Richard |
Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. Journal of gastroenterology and hepatology 2014 Jan 29 (1): 60-6. Hirai Fumihito, Takatsu Noritaka, Yano Yutaka, Satou Yuhou, Takahashi Haruhiko, Ishikawa Satoshi, Tsurumi Kozue, Hisabe Takashi, Matsui Toshiyu |
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clinical pharmacology and therapeutics 2011 Mar 89 (3): 422-8. Herrlinger K R, Koc H, Winter S, Teml A, Stange E F, Fellermann K, Fritz P, Schwab M, Schaeffeler |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: